Academic Journal
Προβολή σε EDS

Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination
Συγγραφείς: Younes, S., Nicolai, E., Pieri, M., Bernardini, S., Daas, H., Al-Sadeq, D., Younes, N., Shurrab, F., Nizamuddin, P., Humaira, F., Al-Dewik, N., Yassine, H., Abu-Raddad, L., Ismail, A., Nasrallah, G.
Συνεισφορές: Younes, S, Nicolai, E, Pieri, M, Bernardini, S, Daas, H, Al-Sadeq, D, Younes, N, Shurrab, F, Nizamuddin, P, Humaira, F, Al-Dewik, N, Yassine, H, Abu-Raddad, L, Ismail, A, Nasrallah, G
Στοιχεία εκδότη: John Wiley and Sons Inc
Έτος έκδοσης: 2024
Συλλογή: Universitá degli Studi di Roma "Tor Vergata": ART - Archivio Istituzionale della Ricerca
Θεματικοί όροι: anti-S-RBD IgG, anti-S1-IgA, antibodies, booster, COVID-19, immune response, neutralizing antibody, vaccination, Settore BIOS-09/A - Biochimica clinica e biologia molecolare clinica
Περιγραφή: Background: Priming with ChAdOx1 followed by heterologous boosting is considered in several countries. Nevertheless, analyses comparing the immunogenicity of heterologous booster to homologous primary vaccination regimens and natural infection are lacking. In this study, we aimed to conduct a comparative assessment of the immunogenicity between homologous primary vaccination regimens and heterologous prime-boost vaccination using BNT162b2 or mRNA-1273. Methods: We matched vaccinated naïve (VN) individuals (n = 673) with partial vaccination (n = 64), primary vaccination (n = 590), and primary series plus mRNA vaccine heterologous booster (n = 19) with unvaccinated naturally infected (NI) individuals with a documented primary SARS-CoV-2 infection (n = 206). We measured the levels of neutralizing total antibodies (NTAbs), total antibodies (TAbs), anti-S-RBD IgG, and anti-S1 IgA titers. Results: Homologous primary vaccination with ChAdOx1 not only showed less potent NTAb, TAb, anti-S-RBD IgG, and anti-S1 IgA immune responses compared to primary BNT162b2 or mRNA-1273 vaccination regimens (p < 0.05) but also showed ~3-fold less anti-S1 IgA response compared to infection-induced immunity (p < 0.001). Nevertheless, a heterologous booster led to an increase of ~12 times in the immune response when compared to two consecutive homologous ChAdOx1 immunizations. Furthermore, correlation analyses revealed that both anti-S-RBD IgG and anti-S1 IgA significantly contributed to virus neutralization among NI individuals, particularly in symptomatic and pauci-symptomatic individuals, whereas among VN individuals, anti-S-RBD IgG was the main contributor to virus neutralization. Conclusion: The results emphasize the potential benefit of using heterologous mRNA boosters to increase antibody levels and neutralizing capacity particularly in patients who received primary vaccination with ChAdOx1.
Τύπος εγγράφου: article in journal/newspaper
Γλώσσα: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/38706402; info:eu-repo/semantics/altIdentifier/wos/WOS:001214246000001; volume:18; issue:5; journal:INFLUENZA AND OTHER RESPIRATORY VIRUSES; https://hdl.handle.net/2108/407423
DOI: 10.1111/irv.13290
Διαθεσιμότητα: https://hdl.handle.net/2108/407423
https://doi.org/10.1111/irv.13290
Rights: info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by/4.0/
Αριθμός Καταχώρησης: edsbas.534FA0FF
Βάση Δεδομένων: BASE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://hdl.handle.net/2108/407423#
    Name: EDS - BASE (ns324271)
    Category: fullText
    Text: View record from BASE
Header DbId: edsbas
DbLabel: BASE
An: edsbas.534FA0FF
RelevancyScore: 945
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 944.983581542969
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Younes%2C+S%2E%22&quot;&gt;Younes, S.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Nicolai%2C+E%2E%22&quot;&gt;Nicolai, E.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pieri%2C+M%2E%22&quot;&gt;Pieri, M.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bernardini%2C+S%2E%22&quot;&gt;Bernardini, S.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Daas%2C+H%2E%22&quot;&gt;Daas, H.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Al-Sadeq%2C+D%2E%22&quot;&gt;Al-Sadeq, D.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Younes%2C+N%2E%22&quot;&gt;Younes, N.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Shurrab%2C+F%2E%22&quot;&gt;Shurrab, F.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Nizamuddin%2C+P%2E%22&quot;&gt;Nizamuddin, P.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Humaira%2C+F%2E%22&quot;&gt;Humaira, F.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Al-Dewik%2C+N%2E%22&quot;&gt;Al-Dewik, N.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Yassine%2C+H%2E%22&quot;&gt;Yassine, H.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Abu-Raddad%2C+L%2E%22&quot;&gt;Abu-Raddad, L.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ismail%2C+A%2E%22&quot;&gt;Ismail, A.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Nasrallah%2C+G%2E%22&quot;&gt;Nasrallah, G.&lt;/searchLink&gt;
– Name: Author
  Label: Contributors
  Group: Au
  Data: Younes, S&lt;br /&gt;Nicolai, E&lt;br /&gt;Pieri, M&lt;br /&gt;Bernardini, S&lt;br /&gt;Daas, H&lt;br /&gt;Al-Sadeq, D&lt;br /&gt;Younes, N&lt;br /&gt;Shurrab, F&lt;br /&gt;Nizamuddin, P&lt;br /&gt;Humaira, F&lt;br /&gt;Al-Dewik, N&lt;br /&gt;Yassine, H&lt;br /&gt;Abu-Raddad, L&lt;br /&gt;Ismail, A&lt;br /&gt;Nasrallah, G
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: John Wiley and Sons Inc
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2024
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: Universit&#225; degli Studi di Roma &quot;Tor Vergata&quot;: ART - Archivio Istituzionale della Ricerca
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22anti-S-RBD+IgG%22&quot;&gt;anti-S-RBD IgG&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22anti-S1-IgA%22&quot;&gt;anti-S1-IgA&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22antibodies%22&quot;&gt;antibodies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22booster%22&quot;&gt;booster&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22COVID-19%22&quot;&gt;COVID-19&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22immune+response%22&quot;&gt;immune response&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22neutralizing+antibody%22&quot;&gt;neutralizing antibody&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22vaccination%22&quot;&gt;vaccination&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Settore+BIOS-09%2FA+-+Biochimica+clinica+e+biologia+molecolare+clinica%22&quot;&gt;Settore BIOS-09/A - Biochimica clinica e biologia molecolare clinica&lt;/searchLink&gt;
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Background: Priming with ChAdOx1 followed by heterologous boosting is considered in several countries. Nevertheless, analyses comparing the immunogenicity of heterologous booster to homologous primary vaccination regimens and natural infection are lacking. In this study, we aimed to conduct a comparative assessment of the immunogenicity between homologous primary vaccination regimens and heterologous prime-boost vaccination using BNT162b2 or mRNA-1273. Methods: We matched vaccinated naïve (VN) individuals (n = 673) with partial vaccination (n = 64), primary vaccination (n = 590), and primary series plus mRNA vaccine heterologous booster (n = 19) with unvaccinated naturally infected (NI) individuals with a documented primary SARS-CoV-2 infection (n = 206). We measured the levels of neutralizing total antibodies (NTAbs), total antibodies (TAbs), anti-S-RBD IgG, and anti-S1 IgA titers. Results: Homologous primary vaccination with ChAdOx1 not only showed less potent NTAb, TAb, anti-S-RBD IgG, and anti-S1 IgA immune responses compared to primary BNT162b2 or mRNA-1273 vaccination regimens (p &lt; 0.05) but also showed ~3-fold less anti-S1 IgA response compared to infection-induced immunity (p &lt; 0.001). Nevertheless, a heterologous booster led to an increase of ~12 times in the immune response when compared to two consecutive homologous ChAdOx1 immunizations. Furthermore, correlation analyses revealed that both anti-S-RBD IgG and anti-S1 IgA significantly contributed to virus neutralization among NI individuals, particularly in symptomatic and pauci-symptomatic individuals, whereas among VN individuals, anti-S-RBD IgG was the main contributor to virus neutralization. Conclusion: The results emphasize the potential benefit of using heterologous mRNA boosters to increase antibody levels and neutralizing capacity particularly in patients who received primary vaccination with ChAdOx1.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article in journal/newspaper
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: info:eu-repo/semantics/altIdentifier/pmid/38706402; info:eu-repo/semantics/altIdentifier/wos/WOS:001214246000001; volume:18; issue:5; journal:INFLUENZA AND OTHER RESPIRATORY VIRUSES; https://hdl.handle.net/2108/407423
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1111/irv.13290
– Name: URL
  Label: Availability
  Group: URL
  Data: https://hdl.handle.net/2108/407423&lt;br /&gt;https://doi.org/10.1111/irv.13290
– Name: Copyright
  Label: Rights
  Group: Cpyrght
  Data: info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by/4.0/
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsbas.534FA0FF
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsbas&AN=edsbas.534FA0FF
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/irv.13290
    Languages:
      – Text: English
    Subjects:
      – SubjectFull: anti-S-RBD IgG
        Type: general
      – SubjectFull: anti-S1-IgA
        Type: general
      – SubjectFull: antibodies
        Type: general
      – SubjectFull: booster
        Type: general
      – SubjectFull: COVID-19
        Type: general
      – SubjectFull: immune response
        Type: general
      – SubjectFull: neutralizing antibody
        Type: general
      – SubjectFull: vaccination
        Type: general
      – SubjectFull: Settore BIOS-09/A - Biochimica clinica e biologia molecolare clinica
        Type: general
    Titles:
      – TitleFull: Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Younes, S.
      – PersonEntity:
          Name:
            NameFull: Nicolai, E.
      – PersonEntity:
          Name:
            NameFull: Pieri, M.
      – PersonEntity:
          Name:
            NameFull: Bernardini, S.
      – PersonEntity:
          Name:
            NameFull: Daas, H.
      – PersonEntity:
          Name:
            NameFull: Al-Sadeq, D.
      – PersonEntity:
          Name:
            NameFull: Younes, N.
      – PersonEntity:
          Name:
            NameFull: Shurrab, F.
      – PersonEntity:
          Name:
            NameFull: Nizamuddin, P.
      – PersonEntity:
          Name:
            NameFull: Humaira, F.
      – PersonEntity:
          Name:
            NameFull: Al-Dewik, N.
      – PersonEntity:
          Name:
            NameFull: Yassine, H.
      – PersonEntity:
          Name:
            NameFull: Abu-Raddad, L.
      – PersonEntity:
          Name:
            NameFull: Ismail, A.
      – PersonEntity:
          Name:
            NameFull: Nasrallah, G.
      – PersonEntity:
          Name:
            NameFull: Younes, S
      – PersonEntity:
          Name:
            NameFull: Nicolai, E
      – PersonEntity:
          Name:
            NameFull: Pieri, M
      – PersonEntity:
          Name:
            NameFull: Bernardini, S
      – PersonEntity:
          Name:
            NameFull: Daas, H
      – PersonEntity:
          Name:
            NameFull: Al-Sadeq, D
      – PersonEntity:
          Name:
            NameFull: Younes, N
      – PersonEntity:
          Name:
            NameFull: Shurrab, F
      – PersonEntity:
          Name:
            NameFull: Nizamuddin, P
      – PersonEntity:
          Name:
            NameFull: Humaira, F
      – PersonEntity:
          Name:
            NameFull: Al-Dewik, N
      – PersonEntity:
          Name:
            NameFull: Yassine, H
      – PersonEntity:
          Name:
            NameFull: Abu-Raddad, L
      – PersonEntity:
          Name:
            NameFull: Ismail, A
      – PersonEntity:
          Name:
            NameFull: Nasrallah, G
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-locals
              Value: edsbas
            – Type: issn-locals
              Value: edsbas.oa
ResultId 1